Hematocrit

Hematocrit, also called Ht, is a biomarker measured as part of a complete blood count (CBC). It is expressed as a percentage and provides a standardized laboratory measure used in blood assessment.

Hematocrit is tested using a whole-blood sample and is reported as a percentage. Fasting is not required for this test, so arranging the collection does not depend on avoiding food beforehand.

When reviewing a result, use the reference information shown for the appropriate sex, as separate male and female ranges are provided. The result can also be considered alongside Hemoglobin and Red Blood Cells, which are related markers displayed with it. These comparisons help place the hematocrit measurement in context rather than treating it as an isolated finding.

The listed ranges distinguish a broader reference range from an optimal range, and the page describes the optimal result as a range rather than a single target. Interpretation should therefore account for which interval is being used and the surrounding clinical context. A clinician can help explain what the result means for an individual, particularly when other blood-test findings or a medical condition are also relevant.

Interpret a hematocrit result against the reference range shown on the same laboratory report. The reference range is the broader interval used for comparison, while the optimal range is narrower. A result can therefore fall within the reference range without being within the tighter optimal range. The applicable interval may also vary by sex, so the range printed for the individual is the relevant one.

Laboratories can use different reference ranges and units, so a number should not be judged against a general online range or another laboratory’s report. The sample for this test is whole blood, and fasting is not required.

A single hematocrit value is not a diagnosis. An out-of-range result belongs with a clinician, who can interpret it in the context of the person’s circumstances and other findings.

Hematocrit was measured directly in studies of Ginkgo Biloba, Echinacea, Reishi, and Saffron Extract. Ginkgo Biloba was associated with a decrease in hematocrit. Echinacea, Reishi, and Saffron Extract did not produce a meaningful change in the marker in the studies that assessed them directly.

These findings describe the direction observed under the studied conditions, not a general effect for every person or product. Hematocrit is interpreted against a range rather than a goal of simply increasing or decreasing it, so the relevance of a change depends on the broader clinical context. Rechecking occurred approximately 4 to 12 weeks after the intervention in these studies. The evidence summarized here concerns direct measurement of hematocrit; it does not establish that an intervention changes the marker merely because it affects a related outcome. Anyone evaluating an abnormal hematocrit or considering an intervention for a medical condition should discuss the findings with a clinician.